Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8393208rdf:typepubmed:Citationlld:pubmed
pubmed-article:8393208lifeskim:mentionsumls-concept:C0206212lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0042615lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0026944lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0042614lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0030092lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0041441lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:8393208lifeskim:mentionsumls-concept:C0112317lld:lifeskim
pubmed-article:8393208pubmed:issue3lld:pubmed
pubmed-article:8393208pubmed:dateCreated1993-8-26lld:pubmed
pubmed-article:8393208pubmed:abstractTextThe activities of danofloxacin, a novel fluoroquinolone, and two other antimicrobials were determined in vitro against field isolates of seven Mycoplasma species of veterinary importance isolated from cattle, swine and poultry in five European countries. The minimum inhibitory concentrations (MIC) of danofloxacin, tylosin and oxytetracycline were determined against a total of 68 isolates. Danofloxacin showed excellent activity against isolates of all Mycoplasma species (range 0.008 to 0.5 microgram ml-1), but in some isolates there was evidence of reduced sensitivity to tylosin (range 0.008 to 2.0 micrograms ml-1) and oxytetracycline (range 0.008 to over 16.0 micrograms ml-1). Danofloxacin was more active than other antimicrobials against M hyopneumoniae, M dispar and M bovigenitalium, and showed activity similar to that of tylosin against M bovis and M gallisepticum. Tylosin was the most active against M synoviae and M hyosynoviae. Generally, oxytetracycline showed the poorest activity, but was superior to tylosin against M bovigenitalium. A second (final) MIC reading was taken for all isolates 14 or 21 days after the initial reading, and MIC values rose during that time. However, the increase seen in danofloxacin values (typically one to two dilutions) was less than that seen for tylosin and oxytetracycline. It is concluded that danofloxacin is highly active in vitro against all of the Mycoplasma species tested, and thus shows great potential for the treatment of respiratory and other infections caused by Mycoplasma species in cattle, pigs and poultry.lld:pubmed
pubmed-article:8393208pubmed:languageenglld:pubmed
pubmed-article:8393208pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:citationSubsetIMlld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8393208pubmed:statusMEDLINElld:pubmed
pubmed-article:8393208pubmed:monthMaylld:pubmed
pubmed-article:8393208pubmed:issn0034-5288lld:pubmed
pubmed-article:8393208pubmed:authorpubmed-author:WiseD RDRlld:pubmed
pubmed-article:8393208pubmed:authorpubmed-author:WhittlestoneP...lld:pubmed
pubmed-article:8393208pubmed:authorpubmed-author:FullerM KMKlld:pubmed
pubmed-article:8393208pubmed:authorpubmed-author:CooperA CAClld:pubmed
pubmed-article:8393208pubmed:authorpubmed-author:FullerJ RJRlld:pubmed
pubmed-article:8393208pubmed:issnTypePrintlld:pubmed
pubmed-article:8393208pubmed:volume54lld:pubmed
pubmed-article:8393208pubmed:ownerNLMlld:pubmed
pubmed-article:8393208pubmed:authorsCompleteYlld:pubmed
pubmed-article:8393208pubmed:pagination329-34lld:pubmed
pubmed-article:8393208pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:meshHeadingpubmed-meshheading:8393208-...lld:pubmed
pubmed-article:8393208pubmed:year1993lld:pubmed
pubmed-article:8393208pubmed:articleTitleIn vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance.lld:pubmed
pubmed-article:8393208pubmed:affiliationCentral Research Division, Pfizer, Sandwich, Kent.lld:pubmed
pubmed-article:8393208pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8393208pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8393208lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8393208lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8393208lld:pubmed